United States: USPTO Releases Examiner Guidance For The Amgen Enablement Decision - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

15 Jan 2024 0 shares 1 views

Mondaq

Published 15 Jan 2024

The USPTO today published its guidance to the examiners on the impact of the Amgen v. Sanofi,143 S. Ct. 1243 (2023), on USPTO practice.

United States: Invalidity Of A Patent Claiming Antibodies Characterized By Their Function In View Of Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

Baxalta Inc. and Baxalta GmbH (Baxalta) appealed a district court decision that the claims of U.S. Patent No. 7,033,590 were..

Mondaq 17 Jan 2024